Nordic Nanovector prices private placement

Nordic Nanovector ASA (OSE:NANO) raised NOK498.7 million ($59.2 million) through the sale of 4.4 million shares at NOK114 in a private placement. DNB Markets, Jefferies and ABG Sundal Collier were underwriters.

Nordic Nanovector intends to use the funds for a planned Phase II study of Betalutin plus Rituxan rituximab to treat non-Hodgkin's lymphoma (NHL) and a Phase I study of an antibody-radionuclide conjugate targeting CD37. Betalutin is a lutetium-177 radiopharmaceutical conjugated to the anti-CD37 mAb lilotomab...